Nanomedicine,
Год журнала:
2024,
Номер
unknown, С. 1 - 26
Опубликована: Дек. 20, 2024
Millions
of
people
worldwide
suffer
from
cancer,
facing
challenges
such
as
treatments
affecting
healthy
cells,
suboptimal
responses,
adverse
effects,
recurrence
risk,
drug
resistance,
and
nonspecific
targeting.
Chemoresistance
leads
to
fatalities,
but
phytoactives
show
promise
in
cancer
management
despite
limitations
high
metabolism,
poor
absorption,
dosage
requirements.
Challenges
the
large-scale
isolation
phytoactive
compounds,
solubility,
bioavailability,
targeting
limit
their
development.
Recent
developments,
including
carbohydrate,
lipid,
protein-based
nanoparticles,
have
enhanced
treatment
by
improving
bioavailability
targeted
delivery
polyphenols,
alkaloids,
sulfur-containing
flavonoids,
terpenes.
Despite
advancements,
clinical
application
faces
hurdles
inconsistent
immune
responses.
This
article
discusses
phytoactive-loaded
nanoformulations
management,
highlighting
delivery,
unmet
needs,
challenges.
Further
research
is
needed
overcome
these
fully
understand
potential
management.
Artificial Cells Nanomedicine and Biotechnology,
Год журнала:
2024,
Номер
52(1), С. 564 - 586
Опубликована: Дек. 5, 2024
Cancer
has
a
high
rate
of
incidence
and
mortality
throughout
the
world.
Although
several
conventional
approaches
have
been
developed
for
treatment
cancer,
such
as
surgery,
chemotherapy,
radiotherapy
thermal
therapy,
they
remarkable
disadvantages
which
result
in
inefficient
cancer.
For
example,
immunogenicity,
prolonged
treatment,
non-specificity,
metastasis
cost
are
considered
major
drawbacks
chemotherapy.
Therefore,
there
is
fundamental
requirement
development
breakthrough
technologies
cancer
suppression.
Polysaccharide-based
drug
delivery
systems
(DDSs)
most
reliable
carriers
therapy.
Polysaccharides,
kind
practical
biomaterials,
divided
into
types,
including
chitosan,
alginates,
dextran,
hyaluronic
acid,
cyclodextrin,
pectin,
etc.
Polysaccharides
extracted
from
different
natural
resources
(like
herbal,
marine,
microorganisms,
etc.).
The
potential
features
polysaccharides
made
them
candidates
therapeutics
to
sites;
simple
purification,
ease
modification
functionalization,
hydrophilicity,
serum
stability,
appropriate
loading
capacity,
biocompatibility,
bioavailability,
biodegradability
stimuli-responsive
sustained
release
manner
considerable
aspects
these
biopolymers.
This
review
highlights
applications
polysaccharides-based
DDSs
pharmaceutical
science
Pharmaceutics,
Год журнала:
2025,
Номер
17(3), С. 280 - 280
Опубликована: Фев. 20, 2025
Central
nervous
system
(CNS)
diseases,
such
as
brain
tumors,
Alzheimer’s
disease,
and
Parkinson’s
significantly
impact
patients’
quality
of
life
impose
substantial
economic
burdens
on
society.
The
blood–brain
barrier
(BBB)
limits
the
effective
delivery
most
therapeutic
drugs,
especially
natural
products,
despite
their
potential
effects.
Trojan
Horse
strategy,
using
nanotechnology
to
disguise
drugs
“cargo”,
enables
them
bypass
BBB,
enhancing
targeting
efficacy.
This
review
explores
applications
products
in
treatment
CNS
discusses
challenges
posed
by
analyzes
advantages
limitations
strategy.
Despite
existing
technical
challenges,
future
research
is
expected
enhance
application
integrating
nanotechnology,
improving
mechanisms,
optimizing
characteristics.
ABSTRACT
Signal
transducer
and
activator
of
transcription
3
(STAT3)
is
a
critical
factor
involved
in
multiple
physiological
pathological
processes.
While
STAT3
plays
an
essential
role
homeostasis,
its
persistent
activation
has
been
implicated
the
pathogenesis
various
diseases,
particularly
cancer,
bone‐related
autoimmune
disorders,
inflammatory
cardiovascular
neurodegenerative
conditions.
The
interleukin‐6/Janus
kinase
(JAK)/STAT3
signaling
axis
central
to
activation,
influencing
tumor
microenvironment
remodeling,
angiogenesis,
immune
evasion,
therapy
resistance.
Despite
extensive
research,
precise
mechanisms
underlying
dysregulated
disease
progression
remain
incompletely
understood,
no
United
States
Food
Drug
Administration
(USFDA)‐approved
direct
inhibitors
currently
exist.
This
review
provides
comprehensive
evaluation
STAT3's
health
disease,
emphasizing
involvement
cancer
stem
cell
maintenance,
metastasis,
inflammation,
drug
We
systematically
discuss
therapeutic
strategies,
including
JAK
(tofacitinib,
ruxolitinib),
Src
Homology
2
domain
(S3I‐201,
STATTIC),
antisense
oligonucleotides
(AZD9150),
nanomedicine‐based
delivery
systems,
which
enhance
specificity
bioavailability
while
reducing
toxicity.
By
integrating
molecular
mechanisms,
pathology,
emerging
interventions,
this
fills
knowledge
gap
STAT3‐targeted
therapy.
Our
insights
into
crosstalk,
epigenetic
regulation,
resistance
offer
foundation
for
developing
next‐generation
with
greater
clinical
efficacy
translational
potential.
